1 HOUSE OF REPRESENTATIVES - FLOOR VERSION
2 STATE OF OKLAHOMA
3 1st Session of the 60th Legislature (2025)
4 ENGROSSED SENATE
BILL NO. 860 By: Weaver of the Senate
5
and
6
Kannady and Humphrey of the
7 House
8
9
10 [ Uniform Controlled Dangerous Substances Act -
11 Schedule I substances - effective date ]
12
13
14 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15 SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-204, as
16 last amended by Section 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
17 2024, Section 2-204), is amended to read as follows:
18 Section 2-204. The controlled substances listed in this section
19 are included in Schedule I and include any material, compound,
20 mixture, or preparation that contains any quantity of the following
21 hallucinogenic substances, their salts, isomers, and salts of
22 isomers, unless specifically excepted, when the existence of these
23 salts, isomers, and salts of isomers is possible within the specific
24 chemical designation.
SB860 HFLR Page 1
BOLD FACE denotes Committee Amendments.

1 A. Any of the following opiates including their isomers,
2 esters, ethers, salts, and salts of isomers, esters, and ethers,
3 unless specifically excepted, when the existence of these isomers,
4 esters, ethers, and salts is possible within the specific chemical
5 designation:
6 1. Acetylmethadol;
7 2. Allylprodine;
8 3. Alphacetylmethadol;
9 4. Alphameprodine;
10 5. Alphamethadol;
11 6. Benzethidine;
12 7. Betacetylmethadol;
13 8. Betameprodine;
14 9. Betamethadol;
15 10. Betaprodine;
16 11. Clonitazene;
17 12. Dextromoramide;
18 13. Dextrorphan (except its methyl ether);
19 14. Diampromide;
20 15. Diethylthiambutene;
21 16. Dimenoxadol;
22 17. Dimepheptanol;
23 18. Dimethylthiambutene;
24 19. Dioxaphetyl butyrate;
SB860 HFLR Page 2
BOLD FACE denotes Committee Amendments.

1 20. Dipipanone;
2 21. Ethylmethylthiambutene;
3 22. Etonitazene;
4 23. Etoxeridine;
5 24. Furethidine;
6 25. Hydroxypethidine;
7 26. Isotonitazene;
8 27. Ketobemidone;
9 28. Levomoramide;
10 29. Levophenacylmorphan;
11 30. Metonitazene;
12 31. Morpheridine;
13 32. N-desethyl isotonitazene;
14 33. N-pyrrolidino protonitazene;
15 34. Noracymethadol;
16 35. Norlevorphanol;
17 36. Normethadone;
18 37. Norpipanone;
19 38. Phenadoxone;
20 39. Phenampromide;
21 40. Phenomorphan;
22 41. Phenoperidine;
23 42. Piritramide;
24 43. Proheptazine;
SB860 HFLR Page 3
BOLD FACE denotes Committee Amendments.

1 44. Properidine;
2 45. Protonitazene;
3 46. Racemoramide; or
4 47. Trimeperidine.
5 B. Any of the following opium derivatives, their salts,
6 isomers, and salts of isomers, unless specifically excepted, when
7 the existence of these salts, isomers, and salts of isomers is
8 possible within the specific chemical designation:
9 1. Acetorphine;
10 2. Acetyldihydrocodeine;
11 3. Benzylmorphine;
12 4. Codeine methylbromide;
13 5. Codeine-N-Oxide;
14 6. Cyprenorphine;
15 7. Desomorphine;
16 8. Dihydromorphine;
17 9. Etorphine;
18 10. Heroin;
19 11. Hydromorphinol;
20 12. Methyldesorphine;
21 13. Methylhydromorphine;
22 14. Morphine methylbromide;
23 15. Morphine methylsulfonate;
24 16. Morphine-N-Oxide;
SB860 HFLR Page 4
BOLD FACE denotes Committee Amendments.

1 17. Myrophine;
2 18. Nicocodeine;
3 19. Nicomorphine;
4 20. Normorphine;
5 21. Phoclodine;
6 22. Thebacon;
7 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
8 (Acetyl fentanyl);
9 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
10 (Crotonyl fentanyl);
11 25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
12 furancarboxamide (Furanyl fentanyl);
13 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
14 27. N-(1-phenethylpiperidin-4-yl)-N-
15 phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
16 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
17 (Butyrl fentanyl).
18 C. Any material, compound, mixture, or preparation which
19 contains any quantity of the following hallucinogenic substances,
20 their salts, isomers, and salts of isomers, unless specifically
21 excepted, when the existence of these salts, isomers, and salts of
22 isomers is possible within the specific chemical designation:
23 1. Methcathinone;
24 2. 3, 4-methylenedioxy amphetamine;
SB860 HFLR Page 5
BOLD FACE denotes Committee Amendments.

1 3. 3, 4-methylenedioxy methamphetamine;
2 4. 5-methoxy-3, 4-methylenedioxy amphetamine;
3 5. 3, 4, 5-trimethoxy amphetamine;
4 6. Bufotenine;
5 7. Diethyltryptamine;
6 8. Dimethyltryptamine;
7 9. 4-methyl-2, 5-dimethoxyamphetamine;
8 10. Ibogaine;
9 11. Lysergic acid diethylamide;
10 12. Marijuana;
11 13. Mescaline;
12 14. N-benzylpiperazine;
13 15. N-ethyl-3-piperidyl benzilate;
14 16. N-methyl-3-piperidyl benzilate;
15 17. Psilocybin;
16 18. Psilocyn;
17 19. 2, 5 dimethoxyamphetamine;
18 20. 4 Bromo-2, 5-dimethoxyamphetamine;
19 21. 4 methoxyamphetamine;
20 22. Cyclohexamine;
21 23. Salvia Divinorum;
22 24. Salvinorin A;
23
24
SB860 HFLR Page 6
BOLD FACE denotes Committee Amendments.

1 25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
2 thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
3 TPCP, TCP;
4 26. Phencyclidine (PCP);
5 27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
6 Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
7 28. 1-(3-trifluoromethylphenyl) piperazine;
8 29. Flunitrazepam;
9 30. B-hydroxy-amphetamine;
10 31. B-ketoamphetamine;
11 32. 2,5-dimethoxy-4-nitroamphetamine;
12 33. 2,5-dimethoxy-4-bromophenethylamine;
13 34. 2,5-dimethoxy-4-chlorophenethylamine;
14 35. 2,5-dimethoxy-4-iodoamphetamine;
15 36. 2,5-dimethoxy-4-iodophenethylamine;
16 37. 2,5-dimethoxy-4-methylphenethylamine;
17 38. 2,5-dimethoxy-4-ethylphenethylamine;
18 39. 2,5-dimethoxy-4-fluorophenethylamine;
19 40. 2,5-dimethoxy-4-nitrophenethylamine;
20 41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
21 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
22 43. 2,5-dimethoxy-4-propylthio-phenethylamine;
23 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
24 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
SB860 HFLR Page 7
BOLD FACE denotes Committee Amendments.

1 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
2 47. 5-methoxy-N, N-dimethyltryptamine;
3 48. N-methyltryptamine;
4 49. A-ethyltryptamine;
5 50. A-methyltryptamine;
6 51. N, N-diethyltryptamine;
7 52. N, N-diisopropyltryptamine;
8 53. N, N-dipropyltryptamine;
9 54. 5-methoxy-a-methyltryptamine;
10 55. 4-hydroxy-N, N-diethyltryptamine;
11 56. 4-hydroxy-N, N-diisopropyltryptamine;
12 57. 5-methoxy-N, N-diisopropyltryptamine;
13 58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
14 59. 3,4-Methylenedioxymethcathinone (Methylone);
15 60. 3,4-Methylenedioxypyrovalerone (MDPV);
16 61. 3-Methylmethcathinone (Metaphedrone);
17 62. 4-Methylmethcathinone (Mephedrone);
18 63. 4-methoxymethcathinone;
19 64. 4-Fluoromethcathinone;
20 65. 3-Fluoromethcathinone;
21 66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
22 67. 2,5-Dimethoxy-4-chloroamphetamine;
23 68. 4-Methylethcathinone;
24 69. Pyrovalerone;
SB860 HFLR Page 8
BOLD FACE denotes Committee Amendments.

1 70. N,N-diallyl-5-methoxytryptamine;
2 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
3 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
4 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
5 74. Alpha-Pyrrolidinopentiophenone;
6 75. 4-Fluoroamphetamine;
7 76. Pentedrone;
8 77. 4’-Methyl-a-pyrrolidinohexaphenone;
9 78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
10 79. 2,5-dimethoxyphenethylamine;
11 80. 1,4-Dibenzylpiperazine;
12 81. N,N-Dimethylamphetamine;
13 82. 4-Fluoromethamphetamine;
14 83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
15 (25C-NBOMe);
16 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
17 (25I-NBOMe);
18 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
19 (25B-NBOMe);
20 86. 1-(4-Fluorophenyl)piperazine;
21 87. Methoxetamine;
22 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
23 methylbenzamide;
24 89. N-ethyl hexadrone;
SB860 HFLR Page 9
BOLD FACE denotes Committee Amendments.

1 90. Isopropyl-U-47700;
2 91. Para-fluorobutyrl fentanyl;
3 92. Para-fluorofentanyl (pFF);
4 93. Fluoro isobutryrl fentanyl;
5 94. 3-Hydroxy Phencyclidine (PCP);
6 95. 3-methoxy Phencyclidine (PCP);
7 96. Flualprazolam; or
8 97. Flubromazolam.
9 D. Unless specifically excepted or unless listed in a different
10 schedule, any material, compound, mixture, or preparation which
11 contains any quantity of the following substances having stimulant
12 or depressant effect on the central nervous system:
13 1. Fenethylline;
14 2. Mecloqualone;
15 3. N-ethylamphetamine;
16 4. Methaqualone;
17 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
18 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
19 oxybate, and sodium oxybutyrate;
20 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
21 manufactured, or promoted for human consumption, with the exception
22 of legitimate food additive and manufacturing purposes;
23
24
SB860 HFLR Page 10
BOLD FACE denotes Committee Amendments.

1 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
2 manufactured for human consumption, with the exception of legitimate
3 food additive and manufacturing purposes;
4 8. Gamma Valerolactone (GVL) as packaged, marketed, or
5 manufactured for human consumption, with the exception of legitimate
6 food additive and manufacturing purposes;
7 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
8 manufactured, or promoted for human consumption with the exception
9 of legitimate manufacturing purposes; or
10 10. N-ethylpentylone.
11 E. 1. The following industrial uses of Gamma-Butyrolactone,
12 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
13 excluded from all schedules of controlled substances under this
14 title:
15 a. pesticides,
16 b. photochemical etching,
17 c. electrolytes of small batteries or capacitors,
18 d. viscosity modifiers in polyurethane,
19 e. surface etching of metal coated plastics,
20 f. organic paint disbursements for water soluble inks,
21 g. pH regulators in the dyeing of wool and polyamide
22 fibers,
23 h. foundry chemistry as a catalyst during curing,
24
SB860 HFLR Page 11
BOLD FACE denotes Committee Amendments.

1 i. curing agents in many coating systems based on
2 urethanes and amides,
3 j. additives and flavoring agents in food, confectionary,
4 and beverage products,
5 k. synthetic fiber and clothing production,
6 l. tetrahydrofuran production,
7 m. gamma butyrolactone production,
8 n. polybutylene terephthalate resin production,
9 o. polyester raw materials for polyurethane elastomers
10 and foams,
11 p. coating resin raw material, and
12 q. as an intermediate in the manufacture of other
13 chemicals and pharmaceuticals.
14 2. At the request of any person, the Director of the Oklahoma
15 State Bureau of Narcotics and Dangerous Drugs Control may exempt any
16 other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
17 Gamma Valerolactone, or 1,4 Butanediol from being included as a
18 Schedule I controlled substance if such product is labeled,
19 marketed, manufactured, and distributed for legitimate industrial
20 use in a manner that reduces or eliminates the likelihood of abuse.
21 3. In making a determination regarding an industrial product,
22 the Director, after notice and hearing, shall consider the
23 following:
24 a. the history and current pattern of abuse,
SB860 HFLR Page 12
BOLD FACE denotes Committee Amendments.

1 b. the name and labeling of the product,
2 c. the intended manner of distribution, advertising, and
3 promotion of the product, and
4 d. other factors as may be relevant to and consistent
5 with the public health and safety.
6 4. The hearing shall be held in accordance with the procedures
7 of the Administrative Procedures Act.
8 F. Any material, compound, mixture, or preparation, whether
9 produced directly or indirectly from a substance of vegetable origin
10 or independently by means of chemical synthesis, or by a combination
11 of extraction and chemical synthesis, that contains any quantity of
12 the following substances, or that contains any of their salts,
13 isomers, and salts of isomers when the existence of these salts,
14 isomers, and salts of isomers is possible within the specific
15 chemical designation:
16 1. JWH-004;
17 2. JWH-007;
18 3. JWH-009;
19 4. JWH-015;
20 5. JWH-016;
21 6. JWH-018;
22 7. JWH-019;
23 8. JWH-020;
24 9. JWH-030;
SB860 HFLR Page 13
BOLD FACE denotes Committee Amendments.

1 10. JWH-046;
2 11. JWH-047;
3 12. JWH-048;
4 13. JWH-049;
5 14. JWH-050;
6 15. JWH-070;
7 16. JWH-071;
8 17. JWH-072;
9 18. JWH-073;
10 19. JWH-076;
11 20. JWH-079;
12 21. JWH-080;
13 22. JWH-081;
14 23. JWH-082;
15 24. JWH-094;
16 25. JWH-096;
17 26. JWH-098;
18 27. JWH-116;
19 28. JWH-120;
20 29. JWH-122;
21 30. JWH-145;
22 31. JWH-146;
23 32. JWH-147;
24 33. JWH-148;
SB860 HFLR Page 14
BOLD FACE denotes Committee Amendments.

1 34. JWH-149;
2 35. JWH-150;
3 36. JWH-156;
4 37. JWH-167;
5 38. JWH-175;
6 39. JWH-180;
7 40. JWH-181;
8 41. JWH-182;
9 42. JWH-184;
10 43. JWH-185;
11 44. JWH-189;
12 45. JWH-192;
13 46. JWH-193;
14 47. JWH-194;
15 48. JWH-195;
16 49. JWH-196;
17 50. JWH-197;
18 51. JWH-198;
19 52. JWH-199;
20 53. JWH-200;
21 54. JWH-201;
22 55. JWH-202;
23 56. JWH-203;
24 57. JWH-204;
SB860 HFLR Page 15
BOLD FACE denotes Committee Amendments.

1 58. JWH-205;
2 59. JWH-206;
3 60. JWH-207;
4 61. JWH-208;
5 62. JWH-209;
6 63. JWH-210;
7 64. JWH-211;
8 65. JWH-212;
9 66. JWH-213;
10 67. JWH-234;
11 68. JWH-235;
12 69. JWH-236;
13 70. JWH-237;
14 71. JWH-239;
15 72. JWH-240;
16 73. JWH-241;
17 74. JWH-242;
18 75. JWH-243;
19 76. JWH-244;
20 77. JWH-245;
21 78. JWH-246;
22 79. JWH-248;
23 80. JWH-249;
24 81. JWH-250;
SB860 HFLR Page 16
BOLD FACE denotes Committee Amendments.

1 82. JWH-251;
2 83. JWH-252;
3 84. JWH-253;
4 85. JWH-262;
5 86. JWH-292;
6 87. JWH-293;
7 88. JWH-302;
8 89. JWH-303;
9 90. JWH-304;
10 91. JWH-305;
11 92. JWH-306;
12 93. JWH-307;
13 94. JWH-308;
14 95. JWH-311;
15 96. JWH-312;
16 97. JWH-313;
17 98. JWH-314;
18 99. JWH-315;
19 100. JWH-316;
20 101. JWH-346;
21 102. JWH-348;
22 103. JWH-363;
23 104. JWH-364;
24 105. JWH-365;
SB860 HFLR Page 17
BOLD FACE denotes Committee Amendments.

1 106. JWH-367;
2 107. JWH-368;
3 108. JWH-369;
4 109. JWH-370;
5 110. JWH-371;
6 111. JWH-373;
7 112. JWH-386;
8 113. JWH-387;
9 114. JWH-392;
10 115. JWH-394;
11 116. JWH-395;
12 117. JWH-397;
13 118. JWH-398;
14 119. JWH-399;
15 120. JWH-400;
16 121. JWH-412;
17 122. JWH-413;
18 123. JWH-414;
19 124. JWH-415;
20 125. CP-55, 940;
21 126. CP-47, 497;
22 127. HU-210;
23 128. HU-211;
24 129. WIN-55, 212-2;
SB860 HFLR Page 18
BOLD FACE denotes Committee Amendments.

1 130. AM-2201;
2 131. AM-2233;
3 132. JWH-018 adamantyl-carboxamide;
4 133. AKB48;
5 134. JWH-122 N-(4-pentenyl)analog;
6 135. MAM2201;
7 136. URB597;
8 137. URB602;
9 138. URB754;
10 139. UR144;
11 140. XLR11;
12 141. A-796,260;
13 142. STS-135;
14 143. AB-FUBINACA;
15 144. AB-PINACA;
16 145. PB-22;
17 146. AKB48 N-5-Fluorpentyl;
18 147. AM1248;
19 148. FUB-PB-22;
20 149. ADB-FUBINACA;
21 150. BB-22;
22 151. 5-Fluoro PB-22; or
23 152. 5-Fluoro AKB-48.
24
SB860 HFLR Page 19
BOLD FACE denotes Committee Amendments.

1 G. In addition to those substances listed in subsection F of
2 this section, unless specifically excepted or unless listed in
3 another schedule, any material, compound, mixture, or preparation
4 which contains any quantity of a synthetic cannabinoid found to be
5 in any of the following chemical groups:
6 1. Naphthoylindoles: any compound containing a 3-(1-
7 naphthoyl)indole structure with or without substitution at the
8 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
9 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
10 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
11 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
12 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
13 halophenyl group, whether or not further substituted on the indole
14 ring to any extent, and whether or not substituted on the naphthyl
15 ring to any extent. Naphthoylindoles include, but are not limited
16 to:
17 a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
18 200),
19 b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
20 c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
21 d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
22 e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
23 f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
24 g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
SB860 HFLR Page 20
BOLD FACE denotes Committee Amendments.

1 h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
2 i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
3 j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
4 k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
5 l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
6 m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
7 (JWH-098),
8 n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
9 o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
10 naphthoyl)indole (AM-1220),
11 p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
12 (MAM-2201), or
13 q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
14 2. Naphthylmethylindoles: any compound containing a 1H-indol-
15 3-yl-(1-naphthyl)methane structure with or without substitution at
16 the nitrogen atom of the indole ring by an alkyl, haloalkyl,
17 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
18 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
19 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
21 phenyl, or halophenyl group, whether or not further substituted on
22 the indole ring to any extent, and whether or not substituted on the
23 naphthyl ring to any extent. Naphthylmethylindoles include, but are
24 not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);
SB860 HFLR Page 21
BOLD FACE denotes Committee Amendments.

1 3. Naphthoylpyrroles: any compound containing a 3-(1-
2 naphthoyl)pyrrole structure with or without substitution at the
3 nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
4 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
5 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
6 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
7 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
8 phenyl, or halophenyl group, whether or not further substituted on
9 the pyrrole ring to any extent, and whether or not substituted on
10 the naphthyl group to any extent. Naphthoylpyrroles include, but
11 are not limited to:
12 a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
13 b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
14 (JWH-370),
15 c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
16 d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);
17 4. Naphthylideneindenes: any compound containing a 1-(1-
18 naphthylmethylene)indene structure with or without substitution at
19 the 3-position of the indene ring by an alkyl, haloalkyl,
20 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
21 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
22 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
23 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
24 phenyl, or halophenyl group, whether or not further substituted on
SB860 HFLR Page 22
BOLD FACE denotes Committee Amendments.

1 the indene group to any extent, and whether or not substituted on
2 the naphthyl group to any extent. Naphthylmethylindenes include,
3 but are not limited to, (1-[(3-pentyl)-1H-inden-1-
4 ylidene)methyl]naphthalene (JWH-176);
5 5. Phenylacetylindoles: any compound containing a 3-
6 phenylacetylindole structure with or without substitution at the
7 nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
9 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
10 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
11 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
12 halophenyl group, whether or not further substituted on the indole
13 ring to any extent, and whether or not substituted on the phenyl
14 ring to any extent. Phenylacetylindoles include, but are not
15 limited to:
16 a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
17 b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
18 (RCS-8),
19 c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
20 d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
21 e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
22 f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);
23 6. Cyclohexylphenols: any compound containing a 2-(3-
24 hydroxycyclohexyl)phenol structure with or without substitution at
SB860 HFLR Page 23
BOLD FACE denotes Committee Amendments.

1 the 5-position of the phenolic ring by an alkyl, haloalkyl,
2 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
3 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
4 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
5 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
6 phenyl, or halophenyl group, and whether or not further substituted
7 on the cyclohexyl ring to any extent. Cyclohexylphenols include,
8 but are not limited to:
9 a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
10 hydroxycyclohexyl]-phenol (CP-47,497),
11 b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
12 phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
13 or
14 c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
15 hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
16 7. Benzoylindoles: any compound containing a 3-(benzoyl)indole
17 structure with or without substitution at the nitrogen atom of the
18 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
20 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
21 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
22 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
23 halophenyl group, whether or not further substituted on the indole
24 ring to any extent, and whether or not substituted on the phenyl
SB860 HFLR Page 24
BOLD FACE denotes Committee Amendments.

1 grou p to any extent. Benzoylindoles include, but are not limited
2 to:
3 a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
4 b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
5 methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
6 c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
7 d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
8 e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
9 iodobenzoyl)indole (AM-2233);
10 8. Cyclopropoylindoles: Any compound containing a 3-
11 (cyclopropoyl)indole structure with substitution at the nitrogen
12 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
14 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
15 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
16 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
17 halophenyl group, whether or not further substituted in the indole
18 ring to any extent, and whether or not substituted in the
19 cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
20 are not limited to:
21 a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
22 (UR-144),
23 b. 1-(5-chloropentyl)-3-(2,2,3,3-
24 tetramethylcyclopropoyl)indole (5Cl-UR-144), or
SB860 HFLR Page 25
BOLD FACE denotes Committee Amendments.

1 c. 1-(5-fluoropentyl)-3-(2,2,3,3-
2 tetramethylcyclopropoyl)indole (XLR11);
3 9. Indole Amides: Any compound containing a 1H-Indole-3-
4 carboxamide structure with or without substitution at the nitrogen
5 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
7 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
8 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
9 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
10 halophenyl group, whether or not substituted at the carboxamide
11 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
12 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
13 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
14 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
15 further substituted in the indole, adamantyl, naphthyl, phenyl,
16 pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
17 Amides include, but are not limited to:
18 a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
19 (2NE1),
20 b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
21 carboxamide (STS-135),
22 c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
23 indole-3-carboxamide (ADBICA),
24
SB860 HFLR Page 26
BOLD FACE denotes Committee Amendments.

1 d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
2 fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
3 e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
4 (NNE1),
5 f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
6 carboxamide (5F-NNE1),
7 g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
8 or
9 h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
10 (5F-SDB-006);
11 10. Indole Esters: Any compound containing a 1H-Indole-3-
12 carboxylate structure with or without substitution at the nitrogen
13 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
15 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
17 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
18 halophenyl group, whether or not substituted at the carboxylate
19 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
20 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
21 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
22 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
23 further substituted in the indole, adamantyl, naphthyl, phenyl,
24
SB860 HFLR Page 27
BOLD FACE denotes Committee Amendments.

1 pyrr ole, quinolinyl, or cycloalkyl rings to any extent. Indole
2 Esters include, but are not limited to:
3 a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
4 22),
5 b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
6 carboxylate (5F-PB-22),
7 c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
8 carboxylate (BB-22),
9 d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
10 carboxylate (FDU-PB-22), or
11 e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
12 carboxylate (NM2201);
13 11. Adamantanoylindoles: Any compound containing an
14 adamantanyl-(1H-indol-3-yl)methanone structure with or without
15 substitution at the nitrogen atom of the indole ring by an alkyl,
16 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
17 benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
18 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
19 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
20 phenyl, or halophenyl group, whether or not further substituted in
21 the indole ring to any extent, and whether or not substituted in the
22 adamantyl ring to any extent. Adamantanoylindoles include, but are
23 not limited to:
24
SB860 HFLR Page 28
BOLD FACE denotes Committee Amendments.

1 a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
2 indol-3-yl]methanone (AM1248), or
3 b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
4 001);
5 12. Carbazole Ketone: Any compound containing (9H-carbazole-3-
6 yl) methanone structure with or without substitution at the nitrogen
7 atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
9 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
10 2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
11 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
12 halophenyl group, with substitution at the carbon of the methanone
13 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
14 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
15 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
16 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
17 further substituted at the carbazole, adamantyl, naphthyl, phenyl,
18 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
19 Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-
20 9H-carbazol-3-yl)methanone (EG-018);
21 13. Benzimidazole Ketone: Any compound containing
22 (benzimidazole-2-yl) methanone structure with or without
23 substitution at either nitrogen atom of the benzimidazole ring by an
24 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
SB860 HFLR Page 29
BOLD FACE denotes Committee Amendments.

1 cycl oalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-
2 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
4 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
5 halophenyl group, with substitution at the carbon of the methanone
6 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
7 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
8 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
9 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
10 further substituted in the benzimidazole, adamantyl, naphthyl,
11 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.
12 Benzimidazole Ketones include, but are not limited to:
13 a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
14 l)methanone (JWH-018 benzimidazole analog), or
15 b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
16 yl)(naphthalen-1-yl)methanone (FUBIMINA); and
17 14. Modified by Replacement: any compound defined in this
18 subsection that is modified by replacement of a carbon with nitrogen
19 in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
20 H. Any material, compound, mixture, extract, or preparation
21 that contains a prohibited kratom product as provided in paragraphs
22 3 and 4 of subsection A of Section 1-1432.4 of this title.
23 I. Any prescription drug approved by the federal Food and Drug
24 Administration under the provisions of Section 505 of the Federal
SB860 HFLR Page 30
BOLD FACE denotes Committee Amendments.

1 Food , Drug, and Cosmetic Act, Title 21 of the United States Code,
2 Section 355, that is designated, rescheduled, or deleted as a
3 controlled substance under federal law by the United States Drug
4 Enforcement Administration shall be excluded from Schedule I and
5 shall be prescribed, distributed, dispensed, or used in accordance
6 with federal law upon the issuance of a notice, final rule, or
7 interim final rule by the United States Drug Enforcement
8 Administration designating, rescheduling, or deleting as a
9 controlled substance such a drug product under federal law, unless
10 and until the State Board of Pharmacy takes action pursuant to
11 Section 2-201 of this title. If the Board of Pharmacy does not take
12 action pursuant to Section 2-201 of this title, the drug product
13 shall be deemed to be designated, rescheduled, or deleted as a
14 controlled substance in accordance with federal law and in
15 compliance with the Uniform Controlled Dangerous Substances Act.
16 SECTION 2. This act shall become effective November 1, 2025.
17
18 COMMITTEE REPORT BY: COMMITTEE ON JUDICIARY AND PUBLIC SAFETY
OVERSIGHT, dated 04/22/2025 - DO PASS, As Amended and Coauthored.
19
20
21
22
23
24
SB860 HFLR Page 31
BOLD FACE denotes Committee Amendments.

[DELETED:  P B W  a K  ]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P p p e v s o p f]
[DELETED:  P c a s t g p p c a t]
[DELETED:  P t t o]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P 1 1 1 1 1 1 1]
[DELETED:  P 1 1 1 1 1 1 1 1 1 1]
[DELETED:  P 1 1 1 1]
[DELETED:  P 1 1 1 1 1 1]
[DELETED:  P 5 5 5]
[DELETED:  P 1 1 1 1 1 1 1]
[DELETED:  P 1 N N N]
[DELETED:  P N N 1 N N]
[DELETED:  P q q q n n]
[DELETED:  P a a]
[DELETED:  P n (]
[DELETED:  P]